Bleeding risk assessment for stroke patients on antithrombotic therapy

Area of Science:

• Neurology
• Cardiology
• Pharmacology

Background:

• Ischemic cerebrovascular events carry a high risk of recurrence.
• Antithrombotic therapy is essential for preventing secondary ischemic events.
• These therapies, however, increase the risk of bleeding complications.

Purpose of the Study:

• To review and present current predictive models for bleeding risk associated with antithrombotic therapy.
• To address the need for better hemorrhage risk assessment in patients with stroke or TIA.

Main Methods:

• Literature review of existing predictive models for bleeding risk.
• Analysis of scales such as CCSC, B2LEED3S, S2TOP-BLEED, and HAS-BLED.
• Comparison of model applicability for antiplatelet therapy versus anticoagulation.

Main Results:

• Several predictive models exist for hemorrhage risk, including intracranial hemorrhage.
• Existing guidelines recommend bleeding risk scores like HAS-BLED for anticoagulated patients.
• There is a lack of specific recommendations for bleeding risk prediction with antiplatelet drugs.

Conclusions:

• Accurate prediction of bleeding risk is vital for optimizing antithrombotic therapy.
• Further research and specific guidelines are needed for assessing bleeding risk with antiplatelet agents.
• This review provides an overview of available tools for managing bleeding risk in stroke and TIA patients.